Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression

Hepatocellular carcinoma (HCC) is one of the most lethal cancer types with insufficient approved therapies, among which lenvatinib is a newly approved multi‐targeted tyrosine kinase inhibitor for frontline advanced HCC treatment. However, resistance to lenvatinib has been reported in HCC treatment r...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Cell Mol Med
Main Authors: Zhao, Zhongwei, Zhang, Dengke, Wu, Fazong, Tu, Jianfei, Song, Jingjing, Xu, Min, Ji, Jiansong
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810959/
https://ncbi.nlm.nih.gov/pubmed/33210432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.16108
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki